Clinical Trials Resource Center


March 31, 2008

Orexo reported positive results from a phase II trial of OX17 for the treatment of gastroesophageal reflux disease (GERD). This controlled trial enrolled fifty-nine subjects in Sweden. The subjects received OX17, omeprazole or famotidine for fourteen days. The primary endpoint was the reduction of acid production between the treatment arms. OX17 significantly reduced the acid production compared to omeprazole on day one. The time with pH>4 the first twelve hours after dosing was on average 60% longer with OX17 compared to omeprazole (p<0.05). After fourteen days treatment with OX17, the time with gastric pH>4 was twice as long as after treatment with famotidine. In addition, the need for rescue medication (antacids) during the fourteen day study period was considerably lower for OX17 compared to both famotidine and omeprazole. Based on the results, Orexo plans to move ahead with the development of OX17.

Related Medical Areas

This information does not represent a Lupus Research Institute endorsement of any listed study. It is merely a notice that the study is available. If you are presently under the care of a physician for lupus or other conditions, you should not disrupt your current program without discussing it with your doctor(s). Do not contact the Lupus Research Institute for information on these studies. Only contact the listed numbers. The Lupus Research Institute does not have any jurisdiction over or further involvement with these studies, other than to make people aware that they are being conducted.